Legend Biotech(US:LEGN)2026-01-14 17:00CARVYKTI Market Leadership - CARVYKTI achieved $1.7 billion in Last Twelve Months (LTM) net trade sales[10, 91] - Over 10,000 patients have been treated with CARVYKTI[11, 22] - CARVYKTI has a manufacturing success rate of 97%[24] - CARVYKTI has a median turnaround time (TAT) of less than 30 days[24] - The company expects 3/4 of CARVYKTI orders to come from 2L-4L (second to fourth line) patients[92] Financial Performance and Profitability - Revenue has scaled nearly 4x since Q2 2023[16] - The company anticipates achieving company-wide operating profit in 2026[13, 92] - Operating margin improved from -142% in Q2 2023 to -16% in Q3 2025[14] - The company has $1 billion in cash, cash equivalents, and time deposits as of September 2025[13, 90] Innovation and Pipeline - The company plans to present in vivo data in the second half of 2026[92] - The company aims to file 1-2 US INDs (Investigational New Drug applications) in the second half of 2026[92]